Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
125results about How to "Improve severity" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Heart failure patient treatment and management device
InactiveUS20050085734A1Improve severityWorsen conditionElectrotherapyElectromyographyDiseasePatients symptoms
A device and method to detect and manage heart failure patient symptoms is provided. Respiration and / or cardiac parameters may be sensed or observed to determine the status of a patient's condition. These symptoms may be classified for appropriate patient disease management. A patient's activity level may be monitored in conjunction with respiration and / or cardiac parameters to provide additional patient status information. These symptoms may be classified for appropriate patient disease management. Pulmonary edema is one condition that may be determined to exist when a respiration parameter is out of range for a given sensed activity level. If edema is determined to be present, the device may be configured to respond to treat the edema.
Owner:RMX
Three dimensional printing material system and method
InactiveUS6610429B2High strengthReduce the amount of solutionAdditive manufacturing apparatusLamination ancillary operationsEngineeringLayer wise
Owner:3D SYST INC
Three dimensional printing material system and method
InactiveUS20020026982A1High strengthReduce the amount of solutionSolid waste managementCeramic shaping apparatusEngineeringLayer wise
The present invention is directed to a 3DP(TM) material system ad method, and an article made therefrom. The method of the present invention includes building cross-sectional portions of a three-dimensional article, and assembling the individual cross-sectional areas in a layer-wise fashion to form a final article. The individual cross-sectional areas are built by using an ink-jet printhead to deliver an aqueous fluid to a particulate material that includes plaster.
Owner:3D SYST INC
Low-energy extractive distillation process for dehydration of aqueous ethanol
ActiveUS20090014313A1Simple distillationEnergy efficientFermented solutions distillation/rectificationOrganic compound preparationChemistryBoiling point
An energy-efficient extractive distillation process for producing anhydrous ethanol from aqueous / ethanol feeds containing any range of ethanol employs an extractive distillation column (EDC) that operates under no or greatly reduced liquid reflux conditions. The EDC can be incorporated into an integrated process for producing anhydrous ethanol used for gasoline blending from fermentation broth. By using a high-boiling extractive distillation solvent, no solvent is entrained by the vapor phase to the EDC overhead stream, even under no liquid reflux conditions. The energy requirement and severity of the EDC can be further improved by limiting ethanol recovery in the EDC. In this partial ethanol recovery design, ethanol which remains in the aqueous stream from the EDC is recovered in a post-distillation column or the aqueous stream is recycled to a front-end pre-distillation column where the ethanol is readily recovered since the VLE curve for ethanol / water is extremely favorable for distillation.
Owner:AMT INT INC +1
Systems and methods for use by an implantable medical device for evaluating ventricular dyssynchrony based on T-wave morphology
ActiveUS7676264B1Simple procedureReduce dyssynchronyElectrocardiographyHeart stimulatorsT waveSeverity/Intensity
Techniques are provided for detecting and evaluating ventricular dyssynchrony based on morphological features of the T-wave and for controlling therapy in response thereto. For example, the number of peaks in the T-wave, the area under the peaks, the number of points of inflection, and the slope of the T-wave can be used to detect ventricular dyssynchrony and evaluate its severity. As ventricular dyssynchrony often arises due to heart failure, the degree of dyssynchrony may also be used as a proxy for tracking the progression of heart failure. Pacing therapy is automatically and adaptively adjusted based on the degree of ventricular dyssynchrony so as to reduce the dyssynchrony and thereby improve cardiac function.
Owner:PACESETTER INC
Methods and compositions for treating schizophrenia using antipsychotic combination therapy
The present invention relates to combination therapies and methods for treating, preventing and / or delaying the onset and / or development of schizophrenia, wherein the combination therapies comprise a hydrogenated pyrido[4,3-b]indole or a pharmaceutically acceptable salt thereof, such as dimebon, and an antipsychotic.
Owner:MEDIVATION TECH INC
Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A Gene
InactiveUS20100088778A1Shorten the timeReduce expensesOrganic active ingredientsNervous disorderEpilepsy syndromesCancer research
A method for the diagnosis of an epilepsy syndrome, including SMEI or an SMEI-related syndrome, in a patient comprising testing for an alteration in the SCN1A gene in a sample obtained from the patient; and if an alteration is identified, comparing said alteration to any one of those listed in Table 3, wherein if said alteration is identical to any one of those listed in Table 3, a diagnosis of an epilepsy syndrome, including SMEI or an SMEI-related syndrome, in said patient is made in accordance with the correlation set forth in Table 3.
Owner:BONOMICS LTD
Prevention of diabetes and prolongation of the honeymoon phase of diabetes by administration of GnRH antagonists
InactiveUS6875843B2Reduce morbidityProlong honeymoon phase of diabetesPeptide/protein ingredientsMetabolism disorderDiabetes mellitusMammal
Owner:CHILDRENS MERCY HOSPITAL
Network failure detection method and network failure detection system
InactiveUS20090265784A1Improve severityGood estimateMemory loss protectionUnauthorized memory use protectionCorrelation coefficientHistogram
A system provides definitions of network states, and identifies a cause for the anomaly upon detection. A traffic measuring portion (characteristic quantity generating portion) counts the number of packets / time slot classified by traffic type with respect to network traffic, generating a characteristic quantity; a memory portion stores information about the characteristic quantity; a portion calculates correlation coefficients between each pair of characteristic quantities classified by traffic type; a portion generates a histogram from correlation coefficients; a portion for determining the severity of an anomaly based on the histogram; a portion evaluates the similarity of an anomaly of interest to a reference anomaly using the occurrence probabilities of correlation coefficients; and a portion assigns a color to each pixel according to its occurrence probability value, generating an n×n picture. Visualization of network state is achieved using probability distribution vectors derived from correlation coefficients obtained from each characteristic quantities pair.
Owner:TOHOKU UNIV
Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
InactiveUS8283116B1Improve efficacyReduced toxicityVectorsCell receptors/surface-antigens/surface-determinantsSpinal muscular atrophiesTranscriptional expression
The present invention provides compounds and assays for the identification and validation of compounds for use in the treatment of spinal muscular atrophy (SMA), in which said compounds up-regulate the post-transcriptional expression of SMN1 or SMN2.
Owner:PTC THERAPEUTICS INC +1
Low-energy extractive distillation process for dehydration of aqueous ethanol
ActiveUS8002953B2Energy efficiencyReduce energy inputFermented solutions distillation/rectificationOrganic compound preparationGas phaseExtractive distillation
Owner:AMT INT INC +1
System and method for treating chronic pain
InactiveUS20080183030A1Improve representationEnhance the imageDiagnosticsSurgeryMedicineChronic pain
In a method and system for treating pain or impairment a video imaging device obtains image frames of a continuous portion of the patient's body including a selected impaired member in proper spatial relationship to a facial image of the patient. A processor coupled to the imaging device processes the image frames to form composite image frames in substantially real time wherein the impaired member is replaced by a virtual image of a corresponding healthy member so as to depict the imaged portion of the patient's body performing healthy movement of the selected impaired member. An interface is coupled to the processor for controlling virtual movement of the impaired limb in the composite image frames, and a display screen is coupled to the processor for displaying at least some of the composite image frames in substantially real time synchronism with operation of the interface.
Owner:HADASIT MEDICAL RES SERVICES & DEVMENT
Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
ActiveUS20090148419A1Improve severityReduce mortalityBiocideMammal material medical ingredientsAllo hsctGraft versus host disease induction
The present invention relates to the use of a particular type of adipose tissue derived mesenchymal stem cells (AD-MSCs), which exert immunosuppressive properties, in the manufacture of a pharmaceutical composition for the prevention and treatment of the graft-versus-host disease (GVHD) produced after allogeneic hematopoietic stem cell transplantation.
Owner:CENT DE INVESTIGACIONES ENERGETICAS MEDIO AMBIENTALLES Y TECNOLOGICAS (C I E M A T) +2
Method and system for enhanced medical triage
InactiveUS7363240B1Shorten the timeReduce in quantityFinanceDiagnostic recording/measuringTriageManagement system
The present invention relates to a method and system for enhanced medical triage in managed care plans that streamlines the conventional medical triage process and referral logic, sends only those insurance claims to an integrated case management system that require medical intervention, matches claims to the right resource at the right time, reduces the time needed to review lost time cases, lessens the number of unnecessary referrals or re-referrals, and further tailors the assignment process of medical insurance claims to medical personnel based on specific market and / or employer dedication.
Owner:THE TRAVELERS INDEMNITY
Printed circuit board design for high speed application
ActiveUS20120228006A1Improve severityMinimize delayCross-talk/noise/interference reductionPrinted circuit aspectsElectricityEngineering
A printed circuit board (PCB) is disclosed. The PCB includes a substrate have a top surface and a bottom surface. A first conductive layer is disposed on the top surface of the substrate. The first conductive layer comprises a first signal net and a second signal net. An outermost insulating layer is disposed on the top surface of the substrate to cover the substrate and the first conductive layer. The outmost insulating layer comprises an opening to expose a portion of the second signal net. And, a second conductive layer is disposed on the outermost insulating layer and substantially covering at least a portion of the first signal net. The second conductive layer is filled into the opening to electrically connect to the second signal net which is able to provide one of a ground potential and a power potential.
Owner:MEDIATEK INC
Chickweed bioherbicides
The present invention relates to the use of a strain of Burkholderia andropogonis for controlling the growth of a weed belonging to the order Caryophyllales. The present invention also provides a method for suppressing weed growth, comprising applying a strain of Burkholderia andropogonis to a weed belonging to the order Caryophyllales. Also provided is a biocontrol composition for controlling the growth of a weed belonging to the order Caryophyllales, the composition comprising a strain of Burkholderia andropogonis, and a suitable medium.
Owner:INNOTECH ALBERTA INC
Intravascular pressure drop derived arterial stiffness and reduction of common mode pressure effect
InactiveUS20160000341A1Improve severityIncrease valueCatheterDiagnostic recording/measuringMedicineArterial stiffness
In some embodiments, a method and / or device are disclosed for measuring a pressure drop over a portion of a body lumen. Optionally, the pressure drop for two different flow conditions may be used to find the stiffness of the lumen. In some embodiments the device may be calibrated, for example by correcting for distortion, for example the common mode pressure distortion. Pressure drop and or stiffness measures may be used to evaluate a treatment procedure and / or a stenosis.
Owner:RAMOT AT TEL AVIV UNIV LTD
Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
InactiveUS20090197808A1Inhibits platelet aggregationSuppress immune responsePeptide/protein ingredientsMicrobiological testing/measurementObstructive Pulmonary DiseasesNeutrophil granulocyte
The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of Respiratory Distress Syndrome (RDS), Bronchopulmonary dysplasia (BPD), chronic lung disease and / or pulmonary fibrosis, Asthma and Chronic Obstructive Pulmonary Disease (COPD). More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans.
Owner:THERABRON THERAPEUTICS INC
Issue unit for placing a processor into a gradual slow mode of operation in response to a detected livelock condition within a processor pipeline
InactiveUS7437539B2Gradual slow downImpact processor performanceDigital computer detailsSpecific program execution arrangementsParallel computingOperation mode
An issue unit for placing a processor into a gradual slow down mode of operation is provided. The gradual slow down mode of operation comprises a plurality of stages of slow down operation of an issue unit in a processor in which the issuance of instructions is slowed in accordance with a staging scheme. The gradual slow down of the processor allows the processor to break out of livelock conditions. Moreover, since the slow down is gradual, the processor may flexibly avoid various degrees of livelock conditions. The mechanisms of the illustrative embodiments impact the overall processor performance based on the severity of the livelock condition by taking a small performance impact on less severe livelock conditions and only increasing the processor performance impact when the livelock condition is more severe.
Owner:INTEL CORP
Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis
InactiveUS20110240012A1Easy to optimizeAlleviate and avoid discomfortAntibacterial agentsPeptide/protein ingredientsNasal polypsNose
The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of nasal rhinitis, nasal sinusitis, chronic rhinosinusitis, and nasal polyposis. More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10 and intranasal route of administration, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans.
Owner:THERABRON THERAPEUTICS INC
Gasoline production by olefin polymerization
InactiveUS20070185359A1Reduce over-polymerizationEasy to convertMolecular sieve catalystsLiquid hydrocarbon mixtures productionButeneFractionation
A process unit for the zeolite-catalyzed conversion of light refinery olefins from an FCC unit such as ethylene, propylene, and butylene to gasoline boiling range motor fuels comprises at least two sequential, serially connected reactors connected in parallel to a fractionation section with at one or two fractionators for separating the reactor effluents into product fraction with an optional recycle stream or streams. The configurations according to this scheme allow the adjustment of reactor temperature and / or pressure and / or space velocity to be based on the reactivities of the olefin compounds present in the LPG streams so that the gasoline produced in each reactor will be separated immediately, to reduce over-polymerization of the gasoline in the low severity reactor and to ensure that gasoline formed in the low severity reactor will not be sent to the higher severity reactor e.g. with a higher reactor temperature, where excessive polymerization to undesirable higher molecular with products may take place.
Owner:EXXON RES & ENG CO
System and methods for minimizing organization risk from users associated with a password breach
ActiveUS10540493B1Risk minimizationImprove severityCosmonautic condition simulationsDigital data authenticationPasswordKnowledge organization
System and methods are disclosed for organizations to run a test against an active directory list to see if any user-provided passwords have been part of an existing data breach. Utilizing information from such a test identifies users that have weak passwords, reused passwords or shared passwords that have been associated with an earlier breach. With this information, the organization can seek to reduce risk by training staff for this specific issue in a timely and appropriate manner to significantly reduce the risk of a future breach by those identified users. Training can be customized and targeted at those users who attempt to use passwords that have been associated with a breach (either of their own account or of another account on the same or related domain.
Owner:KNOWBE4 INC
Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
InactiveUS20060135506A1Increase frequencyImprove severityBiocidePeptide/protein ingredientsCyclooxygenaseTreatment pain
The present invention provides compositions and methods for the treatment of pain, inflammation or inflammation mediated disorders in a subject. More particularly, the invention provides a combination therapy for the treatment of pain, inflammation or inflammation mediated disorders comprising the administration to a subject of a calcium modulating agent in combination with a cyclooxygenase-2 selective inhibitor.
Owner:PHARMACIA CORP
Genome-phenome analyzer and methods of using same
Owner:SIMULCONSULT
Survival motor neuron gene (SMN2) mRNA constructs for post-transcription regulation
InactiveUS9394539B1High expressionEliminate side effectsCell receptors/surface-antigens/surface-determinantsVectorsSpinal muscular atrophiesTranscriptional expression
The present invention provides compounds and assays for the identification and validation of compounds for use in the treatment of spinal muscular atrophy (SMA), in which said compounds up-regulate the post-transcriptional expression of SMN1 or SMN2.
Owner:PTC THERAPEUTICS INC
Method of treating graft versus host disease using adipose derived mesenchymal stem cells
ActiveUS8440177B2Improve severityReduce mortalityBiocideMammal material medical ingredientsHematopoietic stem cell transplantationMesenchymal stem cell
The present invention relates to the use of a particular type of adipose tissue derived mesenchymal stem cells (AD-MSCs), which exert immunosuppressive properties, in the manufacture of a pharmaceutical composition for the prevention and treatment of the graft-versus-host disease (GVHD) produced after allogeneic hematopoietic stem cell transplantation.
Owner:CENT DE INVESTIGACIONES ENERGETICAS +2
Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
InactiveUS20060160776A1Increase frequencyImprove severityBiocidePeptide/protein ingredientsInjury causeMedicine
The present invention provides compositions and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of a cannabinoid agent in combination with a cyclooxygenase-2 selective inhibitor.
Owner:PHARMACIA CORP
Application of optineurin protein in preparing acute hepatic damage diagnosis and treatment products
InactiveCN109453380AImprove severityIncrease (decrease severity)Microbiological testing/measurementDigestive systemDiseaseBavachinin
The invention provides application of optineurin protein in preparing acute hepatic damage diagnosis and treatment products. Experiments prove that the OPTN (optineurin) protein is increased in protein in acute hepatic damage tissues and relieves polarization of macrophages through autophagy to release acute hepatic damage, and accordingly acute hepatic damage can be relieved by expressing the OPTN protein or applying bavachinin. Therefore, the OPTN protein can serve as a specific marker protein for diagnosis and drug therapy of acute hepatic damage, and through the agonist of the bavachinin and overexpression viruses, effectively treats acute hepatic damage to achieve more accurate and quicker diagnosis and treatment of acute hepatic damage. The optineurin protein provides a new therapeutic target and an effective new drug for treating acute hepatic damage.
Owner:ZHEJIANG UNIV
Parallel memory allocator employing liveness metrics
ActiveUS20170075806A1Increase likelihoodImprove severityMemory architecture accessing/allocationInput/output to record carriersParallel computingProgram Thread
A liveness-based memory allocation module operating so that a program thread invoking the memory allocation module is provided with an allocation of memory including a reserve of free heap slots beyond the immediate requirements of the invoking thread. The module receives a parameter representing a thread execution window from an invoking thread; calculates a liveness metric based upon the parameter; calculates a reserve of memory to be passed to the invoking thread based upon the parameter; returns a block of memory corresponding to the calculated reserve of memory. Equations, algorithms, and sampling strategies for calculating liveness metrics are disclosed, as well as a method for adaptive control of the module to achieve a balance between memory efficiency and potential contention as specified by a single control parameter.
Owner:UNIVERSITY OF ROCHESTER
Treating c8-c10 aromatic feed streams to prepare and recover trimethylated benzenes
ActiveUS20140316174A1Boost octaneIncrease severityHydrocarbon by isomerisationMolecular sieve catalystHydrodealkylationMethyl group
Methods are provided for the treatment of a feed stream containing C9 aromatic components to produce mesitylene-containing products. The methods include hydrodealkylating the feed stream to remove C2 and higher alkyl groups from the aromatic components and transalkylating the feed stream to rearrange the distribution of methyl groups among the aromatic components. Disclosed methods also include the treatment of a hydrocarbon feedstock by hydrodealkylation and / or transalkylation in order to produce a hydrocarbon product having an increased mass percentage of mesitylene.
Owner:SWIFT FUELS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com